BeiGene
BGNE
#912
Rank
A$33.62 B
Marketcap
$298.53
Share price
0.15%
Change (1 day)
4.30%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : A$5.16 Billion

According to BeiGene 's latest financial reports the company has A$5.16 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$A$5.19 B-19.4%
2022-12-31$A$6.44 B-23.85%
2021-12-31$A$8.45 B68.1%
2020-12-31$A$5.03 B260.1%
2019-12-31$A$1.39 B-43.86%
2018-12-31$A$2.48 B184.03%
2017-12-31$A$0.87 B79.01%
2016-12-31$A$0.48 B379.9%
2015-12-31$A$0.10 B224.01%
2014-12-31$A$31.48 M-172.52%
2013-12-31$-A$43.42 Million

Net assets for similar companies or competitors

Company Net assets differencediff. Country
A$9.22 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
A$2.14 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA